CYP2C19 and effect of clopidogrel for secondary prevention of major

ischemic events: systematic review and meta-analysis

Cover title: CYP2C19 and clopidogrel effect

Keywords: CYP2C19, Ischemic stroke, TIA, major vascular event, clopidogrel, systematic review

Femke C.C. Kremers (MSc)¹, Jochem van den Biggelaar¹ (BSc), Hester F. Lingsma (PhD)², Ron H.N. van Schaik (PhD)³, Bob Roozenbeek (MD, PhD)¹, Diederik W.J. Dippel (MD, PhD)¹

Affiliations:

¹ Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands

² Department of Public Health, Erasmus MC University Medical Center, Rotterdam, the Netherlands

³ Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, the Netherlands

Corresponding Author: Femke Kremers

f.kremers@erasmusmc.nl

Tables: 1

Figures: 5

Word count: 5536

Abstract

Background: Carriers of the CYP2C19 Loss of Function (LoF) allele may experience decreased efficacy of clopidogrel in secondary prevention after cardiovascular events. Randomized clinical trials of clopidogrel in patients with known CYP2C19 carrier status provided inconsistent results. Our aim was to pool the evidence on the effect of clopidogrel on outcome, according to CYP2C19 LoF status, in a meta-analysis.

Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) on the effect of clopidogrel according to CYP2C19 LoF status in patients with cardiovascular disease and recent TIA or stroke was performed. The primary outcomes were 1) ischemic stroke and 2) major adverse cardiac events (MACE). We used random effects analysis to estimate the effect of clopidogrel as a pooled odds ratio (OR) in carriers and non-carriers of the LoF variant and tested for interaction between clopidogrel and CYP2C19.

Results: We included six RCTs with a total of 15,141 participants comparing combined clopidogrel and aspirin therapy to aspirin monotherapy. The effect of clopidogrel on MACE was OR=0.70 in CYP2C19 non-variant carriers compared to OR=0.84 in CYP2C19 variant carriers (pinteraction=0.13). In patients with a recent TIA or minor ischemic stroke, the OR for the effect of clopidogrel on MACE was OR=0.52 in CYP2C19 non-variant carriers compared to OR=0.84 in CYP2C19 variant carriers (pinteraction=0.02) while in patients with cardiovascular disease the difference in effect was not evident (non-variant carriers OR=0.76, variant carriers OR=0.84, pinteraction=0.50).

Conclusion: Our meta-analysis could not establish that overall, clopidogrel is less effective in patients with a recent MI, minor stroke or TIA and a CYP2C19 LoF genotype. However, the size and direction of the difference in effect warrants further research.

Registration - URL: <u>https://www.crd.york.ac.uk/prospero/</u>; Unique identifier: CRD42021242993.

Keywords: Stroke, Genotype guided treatment, clopidogrel, CYP2C19, meta-analysis

Nonstandard Abbreviations and Acronyms

- MACE Major Cardiovascular Event
- TIA Transient Ischemic Attack
- LoF-Loss-of-function
- IS Ischemic Stroke

ASA - Aspirin

Introduction

Patients with a recent transient ischemic attack (TIA), minor ischemic stroke (IS) or cardiac disease, including acute coronary syndrome (ACS) and atrial fibrillation (AF), are at increased risk of recurrent ischemic events.^{1,2}

Recurrent ischemic events are not uncommon in these high-risk patients, even when they are treated with antiplatelet agents, such as clopidogrel. This may partly be ascribed to the incomplete efficacy of these therapies. Another possible cause for the high numbers of recurrent ischemic events is that some patients are unable to convert the prodrug of clopidogrel to its active metabolite. This conversion is regulated by the hepatic cytochrome p450 enzymes, of which hepatic cytochrome p450 2C19 (CYP2C19) is an important contributor.³

Multiple variant alleles of the *CYP2C19* gene are associated with different levels of activity of the CYP2C19 enzyme. The *17 allele variant (-806T>C; rs12248560) is associated with an increased CYP2C19 activity (Gain-of-function), whereas the *2 (681G>A; rs4244285) and *3 (636G>A; rs4986893) variants are loss-of-function (LoF) alleles and produce a CYP2C19 enzyme with decreased activity. Individuals carrying *2 or *3 alleles are called 'LoF-carriers' and have a reduced clopidogrel metabolism.⁴ These LoF genetic variants occur in approximately 30% of the Western population and in up to 60% in the Asian population.^{3, 5, 6}

The debate on the utility and effectiveness of testing for this purpose is ongoing and several testing strategies have been proposed and described in observational studies. Direct evidence of the interaction of CYP2C19 variants with clopidogrel on recurrent vascular events is not abundantly available.⁷ In the randomized controlled trials that investigated whether clopidogrel + ASA is superior to ASA monotherapy for the prevention of new ischemic events, genetic sub-studies investigated the effect of *CYP2C19* LoF variants on the

effect of clopidogrel treatment.^{5, 8, 9} The results of genetic sub-studies differ, and several studies were not sufficiently powered to detect a difference in effect between subgroups of patients with *CYP2C19* LoF variants.⁷

To create clarity on this subject, we performed a systematic review and meta-analysis to estimate the effect of the *CYP2C19* LoF variants on the effect of clopidogrel treatment in patients with either cardiac ischemic disease or a recent TIA or minor ischemic stroke.

Methods

Search strategy

We performed a comprehensive literature search in the online databases Embase, Medline ALL, Web of Science Core Collection, Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar on March 13, 2023 to include randomized controlled trials (RCT) that investigated patients with cerebrovascular disease or cardiovascular disease treated with clopidogrel versus without clopidogrel and were followed for the occurrence of IS, major bleeding or a composite outcome for major cardiovascular events (MACE) of IS, myocardial infarction (MI), non-central nervous system systemic embolism or vascular death (Supplementary Material I). In the present meta-analysis, we also included trials in patients with cardiovascular disease, such as acute coronary syndrome (ACS), peripheral artery disease (PAD), atrial fibrillation (AF) and patients with multiple cardiovascular risk factors, who are at increased risk of recurrent ischemic events. CYP2C19 status should have been investigated in the trial population by genotyping extracted DNA of the participants.

This systematic review was registered with PROSPERO, the International Prospective Registry of Systematic Reviews (CRD42021242993).¹⁰ We performed this systematic review in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines,¹¹ and we filled out the checklist (Supplementary Table I).

Outcomes

The investigated outcomes were 1) occurrence of fatal or non-fatal ischemic stroke or 2) a major cardiovascular event (MACE; IS, MI, non-central nervous system embolism or vascular death). The safety outcome was a major bleeding event, defined as symptomatic intracranial hemorrhage, intraocular hemorrhage causing vision loss, or other bleeding resulting in substantial hemodynamic compromise requiring treatment.¹²

Study selection

Two assessors (JB and FK) independently screened the retrieved articles by title and abstract to identify studies that met the inclusion criteria. Both assessors had to agree with inclusion after screening the eligible studies based on title and abstract. When discrepancies occurred with full text screening of the articles, the discrepancy was discussed with both assessors until consensus was reached. If multiple publications were based on the same trial, the publication with the most complete dataset was included.

Quality assessment and data extraction

Relevant data were extracted from each trial included in the meta-analysis. The following data were extracted: authors, year of publication sub study, enrollment, participants, ancestry, number participants in sub study, reported LoF-carriers, *CYP2C19* variants, median follow-up period, outcomes, safety outcome, treatment, blinding.

The two assessors (JB and FK) separately evaluated the risk of bias of each included trial by using the Cochrane Collaboration Risk of Bias assessment tool.¹³ The following domains were assessed: random sequence generation, allocation concealment, blinding of participants and personnel, blinding outcome assessment, incomplete outcome data, selective

outcome reporting, and other sources of bias. Items were scored as 'low risk of bias', 'some concerns', or 'high' risk of bias (Supplementary Material II).

Statistical analysis

Based on the reported numbers of outcomes (IS, major bleeding and MACE) in the intervention and control groups we estimated the effect of clopidogrel in each study. The pooled effects in the CYP2C19 groups were estimated with a random effects model. The p-value for interaction was estimated by including an interaction factor between treatment and *CYP2C19* variant subgroup in the random effects model. The interaction was considered statistically significant at p<0.05.

All results are reported as odds ratios (OR) with 95% confidence intervals (CI) and will be presented in forest plots. Heterogeneity was assessed with the Cochran's Q test and the I^2 statistic to evaluate the variance between the studies per outcome for carriers and noncarriers separately. The Cochran' Q test was considered statistically significant at p<0.1. Analyses were stratified for the cardiovascular disease population and the TIA or minor stroke population. Sensitivity analyses were performed by considering "low risk of bias" studies only.

Statistical analyses were performed with R Studio statistical software version 1.3.1093 for the primary outcome and safety outcome. The following packages were used in the analysis: 'glm2', 'readxl', 'lme4', 'meta', 'metafor' and 'forestplot'.

Results

Study selection

The search provided 1233 articles for inclusion. After screening on title and abstract, 131 articles were left for full text assessment. Conference abstracts were excluded. Studies

with genotype-guided treatment allocation and trials that did not investigate the required treatment contrast were excluded after full text assessment. Trials comparing clopidogrel with a different P2Y12-receptor inhibitor such as ticagrelor or prasugrel were excluded. ASA exerts its anti-platelet effect through cyclooxygenase (COX) inhibition instead of the P2Y12-receptor and was therefore accepted as co-medication in the trials. Publications based on the same clinical trial led to exclusion of the least complete publication. In the end, 5 eligible articles describing 6 RCTs were left for inclusion in the meta-analysis (Figure 1, Table I, Supplementary Table III). ^{5, 8, 14-16} These included a total of 15,137 patients of which 5,260 were genotyped with at least one *2 or *3 *CYP2C19* LoF variant allele (Table 1, Supplementary Table II, Supplementary Table III). Publication bias was low in included studies (Figure 2).

Study characteristics

In three studies, the index event was a TIA or minor stroke^{5, 8, 16}, while three other studies included patients with cardiovascular disease. ^{14, 15} Two studies were executed in Asian countries,^{5, 16} the other four were mainly based in Europe or North America.^{8, 14, 15} All studies assessed major vascular events (MACE),^{5, 8, 14-16} and five studies reported major bleeding events. ^{5, 8, 14, 15}

The intervention group of all included trials received clopidogrel (75 mg daily) + ASA. In three studies, participants in the intervention group received a loading dose of clopidogrel varying from 300 to 600 mg.^{5, 8, 14} The control group received ASA + placebo in five studies, in one study the control group only ASA without placebo (Supplementary Table III). ¹⁶ The median follow-up period was 90 days in two trials of early antiplatelet treatment. ^{5, ⁸ The median follow-up period varied from 1,9 years to 5 years in the other studies. ¹⁴⁻¹⁶}

Quality assessment

Risk of bias was low in all included trials for the following domains: random sequence generation, allocation concealment, blinding outcome assessment, incomplete outcome data, and other sources of bias. The domains reporting outcome data and blinding of personnel and participants were assessed as 'some concern' in one study.¹⁶ For that reason, the overall risk of bias judgement for this trial was 'some concerns', all other included trials were scored as 'low risk' (Supplementary Table IV).

Effect of clopidogrel

Two trials assessed IS separately from the composite outcome of MACE, both trials consisted of TIA or minor stroke patients ^{5,8}. The observed effect of clopidogrel on IS was larger in non-carriers (OR:0.51, 95%CI: 0.36-0.73) than in carriers (OR: 0.79, 95%CI: 0.58 - 0.1.08) without a significant interaction effect (p=0.07) (Figure 3). No significant heterogeneity was measured for carriers (p=0.17) and noncarriers (p=0.56).

The effect of clopidogrel for the total population on MACE was larger in non-carriers (OR: 0.70, 95%CI: 0.62-0.80) than in carriers (OR: 0.84, 95%CI: 0.70-1.02), but without significant interaction (p=0.13) (Figure 4). For MACE, carriers showed small to moderate heterogeneity (I^2 =39.18%, p=0.14), while noncarriers showed moderate heterogeneity (I^2 =43.42%, p=0.12) (Figure 4). In TIA or minor stroke patients, the effect of clopidogrel on MACE was larger in non-carriers (OR:0.52, 95%CI: 0.38-0.71) than in carriers (OR: 0.84, 95%CI: 0.64-1.11), with a significant interaction (p=0.02) (Figure 4). The effect of clopidogrel on MACE in the cardiovascular subgroup was larger in non-carriers (OR: 0.76, 95%CI: 0.65-0.88) than in carriers (OR: 0.84, 95%CI: 0.64-1.09) but the difference was smaller and not significant (p=0.50) (Figure 4).

The effect of clopidogrel on major bleeding risk was smaller in non-carriers (OR:1.27, 95%CI: 1.00-1.61) than in carriers (OR: 2.48, 95%CI: 1.57-3.83), with a significant

interaction (p=0.01) (Figure 5). No significant heterogeneity was measured (I^2 =16.62%, p=0.31).

In the cardiovascular disease population, the effect of clopidogrel treatment was smaller in non-carriers (OR: 1.28, 95%CI:1.01-1.62) than in carriers (OR:2.36, 95%CI:1.49-3.83) with an interaction of p=0.02 (Figure 5). Because of the low number of bleeding events in the included trials, the effect of clopidogrel on major bleeding in patients with TIA or minor stroke could not be estimated.

In the sensitivity analysis with only low risk of bias trials included, the results were consistent, although the p-value in the TIA or minor stroke population for MACE was not significant (p = 0.08).

Discussion

In this systematic review and meta-analysis, we evaluated how *CYP2C19* LoF allelic variants influence the effect of clopidogrel on the occurrence of major vascular events or major bleeding in patients with a recent TIA, minor stroke or cardiovascular disease. After combining data from 6 studies in patients with TIA, minor IS or cardiovascular disease, we found a reduction of effect of clopidogrel in CY2C19 variant carriers with an OR of 0.84 (95%CI 0.7-1.02) compared to 0.70 (95%CI 0.62-0.80) in non-carriers (p_{interaction}=0.13). In the subgroup of patients with ischemic stroke, the risk of MACE was significantly higher compared to non-carriers (0.84 (95%CI 0.64-1.11 vs. 0.52, 95%CI 0.38-0.71, p_{interaction}=0.02).

The protective effect of clopidogrel on the occurrence of MACE may be diminished in patients with TIA or minor stroke due to the *CYP2C19* LoF variant but our results are not decisive. The interaction of the *CYP2C19* LoF variant with clopidogrel on the occurrence of ischemic stroke seemed less in carriers, but could not be proven since the interaction was not statistically significant. The interaction of the *CYP2C19* LoF variant with clopidogrel effect on MACE was not also statistically significant overall, and the significant interaction of effect

of clopidogrel on MACE in studies of patients with TIA or minor stroke may represent a type 1 error in an overall neutral analysis.

The direction of the interaction was however consistent in the two major subgroups. The effect of clopidogrel by carrier status was significant in patients with a recent TIA or minor stroke, but may have been a type I error caused by multiplicity. In addition, and rather surprisingly, the risk of major bleeding was significantly higher in carriers of the *CYP2C19* allele compared to non-carriers when on clopidogrel treatment.

The association between clopidogrel and *CYP2C19* LoF variants has been investigated in other settings.¹⁷⁻¹⁹ Some studies have performed a meta-analysis to assess the influence of *CYP2C19* LoF variants in patients with a history of cardiovascular disease only. Only one meta-analysis assessed influence of *CYP2C19* LoF variants on TIA and minor stroke patients.⁹ In these studies, the beneficial effect of clopidogrel treatment on ischemic events in patients with a LoF variant was smaller than in patients without a LoF variant. These metaanalyses included randomized controlled trials, case-control studies and cohort studies, which makes them difficult to interpret. In our study, we only included randomized controlled trials, in order to minimize confounding and selection bias. In addition, most of the published metaanalyses did not assess interaction to assess the unbiased effect of a *CYP2C19* LoF variant on clopidogrel efficacy with random effects modelling.

Our study population consisted of participants with different manifestations of vascular disease and therefore different pathophysiological mechanisms leading to ischemic events. Clopidogrel has platelet aggregation lowering properties through inhibition of the P2Y12-receptor on platelets, to prevent thrombus formation in the blood vessels. Compared to cardiac ischemia, a minor ischemic stroke or TIA is more often caused by a blockage of the blood vessel with a thrombo-embolus. ²⁰ Cardiac ischemia, on the other hand, is more often

caused by reduced coronary artery perfusion due to local atherosclerosis. ^{21, 22} The difference in pathophysiology and the point of application of the active substances of clopidogrel may explain why no significant interaction effect was found in the cardiac disease population, although a significant relationship between *CYP2C19* LoF variants and clopidogrel effectiveness has been observed in other studies for patients with cardiac disease. ²³

In addition to the available literature on the relationship of *CYP2C19* LoF variants and clopidogrel efficacy, multiple studies have been performed to investigate the implementation of genotype-guided therapy. ²³⁻²⁸ These studies have mainly been performed for patients with a history of cardiovascular disease ^{26, 29} and they show promising results regarding implementation of genotype-guided treatment but were not conclusive. ^{23, 30-32} In the CHANCE-2 trial, minor stroke patients with a *CYP2C19* LoF mutation showed better response on treatment with ticagrelor and aspirin compared to treatment with clopidogrel and aspirin. ²⁸

More studies on genotype-guided treatment for patients with cardiovascular disease as well as patients with a recent TIA or minor stroke and the implementation in real clinical practice are needed.

Limitations

Our study has several limitations. All studies were performed as a post-hoc analysis. Patients were genotyped for inclusion in a genetic sub-study of the original trial. In most studies, the genotype had been determined in only a small proportion of patients from the original trial. Only one fifth of the participants in the POINT and ACTIVE-A trial were genotyped for *CYP2C19* LoF variants.^{8, 14} However, as the trials were all randomized, selection and confounding bias is unlikely. Third, in the subgroup of trials assessing clopidogrel effect in patients with a TIA or minor stroke, 60% of all events were from the CHANCE trial. The number of events was considerably smaller in the two remaining trials

(Yi et al., POINT). Therefore, the CHANCE trial has played a major role in the effect found for the TIA/minor stroke population. The absence of a differential effect of CYP2C19 in the POINT trial may have been caused by the higher clopidogrel loading dose of 600 mg that was employed. ^{33, 34} In the POINT trial, most events occurred within the first 48h after randomization, which is consistent with earlier studies.^{1, 2} This higher loading dose could have prevented more events in the first days compared to the CHANCE trial, which could be one of the causes of the difference between the results of these trials. A higher dose of clopidogrel maintenance treatment may influence the effectiveness on patients with 1 loss-of function allele.

Studies consisted of heterogenous patient populations, since the outcome of a cardiac event differed per study. Although we performed separated analyses according to the population, the comparability of the populations may limit the interpretation of the findings. In the CURE study, patients with acute coronary syndrome were included, while in the ACTIVE-A patients with atrial fibrillation were analyzed. In the CHARISMA trial, a subgroup of TIA/IS patients were also included in the patient population.

Patients with one *CYP2C19* LoF allele and one functioning allele are considered intermediate metabolizers, whereas poor metabolizers have very low conversion of clopidogrel to its active metabolite by CYP2C19. When patients have suboptimal conversion of clopidogrel and therefore less effective platelet inhibition, these patients may benefit from a higher loading and maintenance dose of clopidogrel. ^{35, 36} However, no consensus exists on the effectiveness of a higher maintenance dose of clopidogrel for patients with a *CYP2C19* LoF variant allele.^{37, 38}

In the present study, only carriers vs. noncarriers of the *CYP2C19* allele were analyzed. We did not separately investigate poor and intermediate metabolizers of CYP2C19, since the number of events for each outcome within the poor metabolizer group was very

small in all included studies. The investigated patient population mainly consisted of intermediate metabolizers (Table 1).

In the POINT trial, baseline National Institutes of Health Stroke Scale (NIHSS) for minor ischemic stroke or TIA patients was 2.⁸ In the CHANCE trial, the baseline NIHSS score was less than 3 for inclusion, and in the article of Yi et al, this was approximately 11 points.^{5, 16} Since in the 2 largest trials (CHANCE and POINT) the baseline NIHSS was low, caution is needed to extrapolate these results in real clinical practice, where patients often experience more disabilities at presentation.

We assessed safety outcomes as events of major bleeding for both patients with cardiovascular disease and patients with a history of TIA or minor stroke. Unfortunately, we could not assess the effect of CYP2C19 on bleeding events for patients with TIA or minor stroke due to a small number of events, which made it statistically inaccurate to interpret these results. For patients with cardiovascular disease and for the overall pooled results, the adverse effect of bleeding due to clopidogrel treatment was higher in patients with a *CYP2C19* LoF variant allele compared to patients without a LoF variant. This finding is not in agreement with earlier studies which showed lower bleeding rates in patients with a *CYP2C19* LoF variant. ^{9, 39, 40} More research is needed to assess the effect of a LoF variants on bleeding events in patients with TIA, minor stroke or cardiovascular disease.

Recent AHA or ESC guidelines do not address CYP2C19 genotyping, nor does the ESO guideline on antithrombotic treatment for stroke prevention. ⁴¹⁻⁴⁵ Future studies regarding cost-effectiveness and effect in real life settings of *CYP2C19* genotype guided testing may provide insight in its prevention of recurrent ischemic events.

Conclusion

Our meta-analysis could not establish that overall, clopidogrel is less effective in patients with a recent MI, minor stroke or TIA and a *CYP2C19* LoF genotype. However, the size and direction of the difference in effect warrants further research into the role of LoF genotypes and the cost-effectiveness of testing.

Supplemental Materials

Supplementary Material I, II

Supplementary Tables I – IV

Disclosures

Drs Kremers, dr van den Biggelaar and other authors report no conflicts of interest.

References

1. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. Bmj. 2004:326.

2. Kleindorfer D, Panagos P, Pancioli A, Khoury J, Kissela B, Woo D, et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke. 2005:720-3.

3. Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, et al. Clopidogrel Pharmacogenetics. Circ Cardiovasc Interv. 2019:e007811.

4. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011:328-32.

5. Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016:70-8.

6. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009:849-57.

7. Kranendonk J, Willems LH, Vijver-Coppen RV, Coenen M, Adang E, Donders R, et al. CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). Am Heart J. 2022:141-8.

8. Meschia JF, Walton RL, Farrugia LP, Ross OA, Ross OA, Elm JJ, et al. Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke. 2020:2058-65.

9. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, et al. Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. Circulation. 2017:21-33.

10. Chien PF, Khan KS, Siassakos D. Registration of systematic reviews: PROSPERO. BJOG. 2012:903-5.

11. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009:e123-30.

12. GUSTO-investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993:673-82.

13. Higgins JPT, Savović J, Page MJ, Sterne JAC, Group obotRD. Revised Cochrane riskof-bias tool for randomized trials (RoB 2). 2019.

14. Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. New Engl J Med. 2010:1704-14.

15. Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KAA, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The CHARISMA genetics study. Eur Heart J. 2012:2143-50.

16. Yi X, Lin J, Zhou J, Wang Y, Huang R, Wang C. The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke. Oncotarget. 2018:17725-34.

17. Niu X, Mao L, Huang Y, Baral S, Li JY, Gao Y, et al. CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2015:147-56.

18. Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomas M, et al. Metaanalyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012:100-8.

19. Biswas M, Kali SK. Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis. Cardiovasc Drugs Ther. 2021.

20. Panuganti KK, Tadi P, Lui F. Transient Ischemic Attack. StatPearls: Treasure Island (FL): StatPearls Publishing; 2021.

21. Lu L, Liu M, Sun R, Zheng Y, Zhang P. Myocardial Infarction: Symptoms and Treatments. Cell Biochem Biophys. 2015:865-7.

22. Makki N, Brennan TM, Girotra S. Acute coronary syndrome. J Intensive Care Med. 2015:186-200.

23. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van 't Hof AWJ, van der Harst P, et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med. 2019:1621-31.

24. Tuteja S, Glick H, Matthai W, Nachamkin I, Nathan A, Monono K, et al. Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Pragmatic Randomized Clinical Trial. Circ Genom Precis Med. 2020:e002640.

25. Xie X, Ma YT, Yang YN, Li XM, Zheng YY, Ma X, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: A randomized control trial. Int J Cardiol. 2013:3736-40.

26. You J, Li H, Guo W, Li J, Gao L, Wang Y, et al. Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study. Catheter Cardiovasc Interv. 2020:598-605.

27. Shen DL, Wang B, Bai J, Han Q, Liu C, Huang XH, et al. Clinical Value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population. J Cardiovasc Pharmacol. 2016:232-6.

28. Wang Y MX, Wang A, Xie X, Pan Y, Johnston SC, Li H, Bath PM, Dong Q, Xu A, Jing J, Lin J, Niu S, Wang Y, Zhao X, Li Z, Jiang Y, Li W, Liu L, Xu J, Chang L, Wang L, Zhuang X, Zhao J, Feng Y, Man H, Li G, Wang B; CHANCE-2 Investigators. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. N Engl J Med. 2021

29. Mega JL, Hochholzer W, Frelinger IAL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J Am Med Assoc. 2011:2221-8.

30. Bauer T, Bouman HJ, Van Werkum JW, Ford NF, Ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: Systematic review and meta-analysis. BMJ (Online). 2011:343:d4588.

31. Galli M, Benenati S, Capodanno D, Franchi F, Rollini F, D'Amario D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2021:1470-83.

32. Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. Jama. 2020:761-71.

33. Nijjer SS, Davies JE, Francis DP. Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. Int J Cardiol. 2012:181-5.

34. Gurbel PA, Shuldiner AR, Bliden KP, Ryan K, Pakyz RE, Tantry US. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J. 2011:598-604.

35. Chen S, Zhang Y, Wang L, Geng Y, Gu J, Hao Q, et al. Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI). Med Sci Monit. 2017:3824-30.

36. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res. 2008:463-8.

37. Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X, et al. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Thromb Res. 2015:449-58.

38. Tang YD, Wang W, Yang M, Zhang K, Chen J, Qiao S, et al. Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial. Circulation. 2018:2231-45.

39. Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A metaanalysis based on 23,035 subjects. Arch Cardiovasc Dis. 2013:517-27.

40. Li JL, Fu Y, Qin SB, Liang GK, Liu J, Nie XY, et al. Association between P2RY12 gene polymorphisms and adverse clinical events in coronary artery disease patients treated with clopidogrel: A systematic review and meta-analysis. Gene. 2018:69-80.

41. Brown DL, Levine DA, Albright K, Kapral MK, Leung LY, Reeves MJ, et al. Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2021:e468-e79.

42. Kamran H, Jneid H, Kayani WT, Virani SS, Levine GN, Nambi V, et al. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA. 2021:1545-55.
43. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021:e364-e467.

44. Klijn CJ, Paciaroni M, Berge E, Korompoki E, Korv J, Lal A, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J. 2019:198-223.

45. Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. European Heart Journal. 2021:4013-24.

Figure legends

Table 1: Study characteristics of the included trials

Figure 1: Flow diagram of selection procedure

Figure 2: Funnel plot for publication bias in included studies


Figure 3: Effect of CYP2C19 variant and occurrence of ischemic stroke


Figure 4: Effect of CYP2C19 variant and treatment on major vascular events

Figure 5: Effect of CYP2C19 variant and treatment on major bleeding

Study	Enrollment	Year of publication	Participants	Ancestry sub study (%)	Participants sub study <i>n</i>	LoF reporte d n (%)	CYP2C19 variants	Median Follow- up	Treatment	Loading + maintenanc e dose clopidogrel (mg)	Blinding
CHANCE ⁵	Oct 2009 - Jul 2012	2016	Acute minor IS, TIA	Asian	2933	1726 (58.8)	*2, *3, *17	90 days	Clopidogrel +ASA vs. Placebo + ASA	300 + 75	Double
POINT ⁸	May 2010 - Dec 2017	2020	Acute minor IS, TIA	White (70.8), Afro/Black- Americans (23.2), other (6.0)	932	265 (28.4)	*2, *3, *17	90 days	Clopidogrel +ASA vs. Placebo + ASA	600 + 75	Double
CURE ¹⁴	Dec 1998 - Sep 2000	2010	ACS without ST-segment elevation	European (85.9), Latin American (14.1)	5030	1325 (26.3)	*2, *3, *17	1.91 years	Clopidogrel +ASA vs. Placebo + ASA	300 + 75	Double
ACTIVE - A ¹⁴	Jun 2003 - May 2006	2010	AF	European	1139	279 (24.5)	*2, *3, *17	3.6 years	Clopidogrel +ASA vs. Placebo + ASA	NI + 75	Double
CHARISM A ¹⁵	Oct 2002- Nov 2003	2012	CAD, Multiple athero- thrombotic risk factors, PAD*, cerebrovascu lar disease	European	4537	1006 (22.2)	*2, *3, *17	2,3 years	Clopidogrel +ASA vs. Placebo + ASA	NI + 75	Double Double
Yi et al. ¹⁶	Aug 2009 - Dec 2011	2018	IS	Asian	570	257 (45.1)	*2,	5 years	Clopidogrel +ASA vs. ASA	NI + 75	NI*

Table 1. Study characteristics of the included trials. *NI = no information mentioned










Figure 3. Effect of CYP2C19 variant and treatment on occurrence of ischemic stroke

Ischemic stroke	Events clopidogrel	No events clopidogrel	Events no clopidogrel	No events no clopidogre	i		Odds Ratio (OR)	2.5% CI	97.5% CI
POINT trial									
Carriers	3	128	9	125		•	0.33	0.07	1.12
Noncarriers	11	315	18	323			0.63	0.28	1.33
CHANCE trial									
Carriers	78	776	93	779			0.84	0.61	1.16
Noncarriers	39	570	74	524			0.48	0.32	0.72
Pooled results									
Carriers						-	0.79	0.58	1.08
Noncarriers P-value for interaction: 0.07						-	0.51	0.36	0.73
Test of heterogeneity carriers: I*2: 46.1% p=0.17, non carriers: I*2: 0.0% p=0.56					0.099 0.177	0.354 0.707	2.50		

Figure 4. Effect of CYP2C19

variant alleles and treatment

on composite major

cardiovascular events

(MACE)

Composite outcome	Events clopidogrel	No events clopidogrel	Events no clopidogrel	No events no clopidogrel		Odds Ratio (OR)	2.5% CI	97.5% 0
TIA/IS								
POINT trial								
Carriers	3	128	9	125 🔷		0.33	0.07	1.12
Noncarriers	12	314	19	322		0.65	0.3	1.34
CHANCE trial								
Carriers	78	776	94	778	— •—	0.83	0.61	1.14
Noncarriers	39	570	74	524		0.48	0.32	0.72
Yi et al.								
Carriers	29	99	27	102		1.11	0.61	2.01
Noncarriers	18	138	31	126		0.53	0.28	0.99
Pooled TIA/IS								
Carriers					-	0.84	0.64	1.11
Noncarriers					1	0.52	0.38	0.71
P-value for interaction: 0.02* Carriers: I^2: 44.77% p=0.18, Noncarriers: I^2: 0.0% p=0.50)								
Cardiac disease								
ACTIVE-A								
Carriers	29	110	35	105	·····	0.79	0.45	1.38
Voncarriers	84	338	118	320		0.79	0.49	0.93
CURE trial	04	330	110	320		0.07	0.49	0.95
Carriers	52	599	78	596		0.66	0.46	0.96
Noncarriers	179	1707	236	1583		0.7	0.57	0.86
CHARISMA trial								
Carriers	36	476	25	469		- 1.42	0.84	2.42
Noncarriers	92	1504	97	1544		0.97	0.73	1.31
Pooled cardiac disease								
Carriers Noncarriers					-	0.84	0.64	1.09
P-value for interaction: 0.50 Carriers: I^2: 51.13% p=0.11, Noncarriers: I^2: 39.86% p=0.17)					-	0.76	0.65	0.88
Carriers. F.2. 51.13% p=0.11, Noncarriers. F.2. 59.00% p=0.17)								
Pooled total					-	0.84	0.7	1.02
Carriers								
					•	0.7	0.62	0.8
Carriers Noncarriers					-	0.7	0.62	0.8

Figure 5. Effect of CYP2C19

variant alleles and treatment on

major bleeding

major bleeding	Events clopidogrel	No events clopidogrel	Events no clopidogrel	No events no clopidogrel		Odds Ratio (OR)	2.5% CI	97.5% C
TIA/IS	25 - 65	18 18	35 W					
POINT trial								
Carriers	0	131	0	134		•		•
Noncarriers	4	322	3	338				
CHANCE trial								
Carriers	3	851	0	872		•	-	
Noncarriers	0	609	1	597				
Pooled TIA/IS								
Carriers Noncarriers						•	•	-
P-value for interaction: 0.92 (Carriers: I^2: 0.0%, p=0.44; Noncarriers: I^2: 0.0%, p=0.92)						1.	·	
Cardiac disease								
ACTIVE-A								
Carriers		125	6	134		2.39	0.95	6.66
Noncarriers	18	404	17	421		1.1	0.56	2.16
CURE trial								
Carriers	21	630	15	659		1.45	0.75	2.86
Noncarriers	81	1805	60	1759		1.31	0.94	1.85
CHARISMA trial								
Carriers	22	437	5	488		4.57	1.91	13.03
Noncarriers	60	1557	47	1570		1.28	0.87	1.9
Pooled cardiac disease								
Carriers						2.36	1.49	3.83
Noncarriers					-	1.28	1.01	1.62
P-value for interaction: 0.02* (Carriers: I^2: 50.70%, p=0.13; Noncarriers: I^2: 0.0%, p=0.90)								
Pooled total								
Carriers						2.48	1.57	4.02
Noncarriers P-value for interaction: 0.01*					-	1.27	1	1.61
Test for heterogeneity								
Carriers: I^2: 16.62%, p=0.31; Noncarriers: I^2: 0.0%, p=0.44						1		

Major bleeding

0.088 0.177 0.354 0.707 2.50